Release Date: July 20, 2015 | Expiration Date: July 20, 2016
Media: Print with online posttest, evaluation, and request for credit
OverviewThis activity is designed to aid physicians in assessing patients with non-small cell lung cancer (NSCLC), including the applicability of testing for mutations and the use of emerging treatments for both squamous and nonsquamous NSCLC.
Instructions For This Activity & Receiving Credit
This activity is directed toward medical oncologists who manage and treat patients with NSCLC. Surgical oncologists, radiation oncologists, pathologists, fellows, nurses, nurse practitioners, physician assistants, and other healthcare providers interested in the treatment of NSCLC are also invited to participate.
Learning ObjectivesAfter participating in this CME activity, learners should be better prepared to:
- List the challenges of measuring PD-L1 levels
- Summarize findings of recent clinical trials that focus on immune-oncology agents for use in patients with non-small cell lung cancer
- Identify emerging agents for the treatment of brain metastases in patients with non-small cell lung cancer
- Describe current data on the role of third-generation EGFR TKIs in the frontline setting of non-small cell lung cancer
Allison A. Muller, PharmD, DABAT
Disclosure: No relevant financial relationships with commercial interests to disclose.
The American Journal of Hematology/ Oncology® Editorial Board
Debu Tripathy, MD
Professor of Medicine and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Disclosure: Grant/research support from Genentech/Roche, Pfizer, Puma Inc, and Novartis (clinical trial support contracted to the University of Southern California and MD Anderson Cancer Center); consultant for Eisai, Oncoplex Diagnostics, Merck, and Novartis.
FacultyHeather A. Wakelee, MD
Associate Professor, Medicine (Oncology)
Stanford University Medical Center
Disclosure: Consultant: Grant/Research Support: Roche, Genentech, MedImmune, Pfizer, Lilly; Consultant: Peregrine Pharmaceuticals, and Novartis
Staff/Planner Disclosures and Conflict of Interest Resolution
The staff of Physicians' Education Resource®, LLC (PER®), LLC (Ann C. Lichti, CHCP, Michael Perlmutter, PharmD, MS, and Kerry Clayton) as well as the editorial staff of The American Journal of Hematology/Oncology® (Devera Pine) have no relevant financial relationships with commercial interests to disclose.
In accordance with Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial SupportSM, PER® resolved all conflicts of interest (COI) prior to the release of this CME activity using a multistep process.
Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is funded by Physicians' Education Resource®.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
DisclaimerThe opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
Hardware And Software RequirementsSupported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise